The study is being conducted in the U.S. and financed by MedinCell’s partner, Arthritis Innovation Corporation (AIC)
F14 (mdc-CWM) is a sustained-release formulation of the non-steroidal anti-inflammatory drug (NSAID), celecoxib, administered intraarticularly at the end of Total Knee Replacement surgery (TKR)
The investigational product aims to facilitate patient recovery by providing post-operative pain relief for weeks and accelerating improvement in knee function, and potentially decreasing the need for addictive opioids
The 150-patient, multicenter, randomized, double blind Phase 3 safety and efficacy trial was designed in consultation with the U.S. FDA
F14 (mdc-CWM) is the third product using MedinCell’s proprietary technology BEPO® to reach or to have completed a Phase 3 clinical trial
Contacts
MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
November 7, 2022